How RCM Performance Drives ASC Valuation Multiples in 2026

Bypaulgruensfelder
VMG HEALTH April 23, 2026
Read Full Article →
AI-Generated Summary

Ambulatory surgery centers preparing to sell in 2026 are seeing buyers price deals on revenue cycle performance as much as case volume, according to VMG Health. Historical ASC sale multiples have run 7-8x EBITDA, with best-in-class centers commanding double-digit multiples, but VMG Health’s deal team says buyers now apply heavier diligence to collections discipline, payer mix, and denial management before underwriting that premium. The firm, drawing on transactions led by Christa Shephard, Chad Zoretic, Debra Stinchcomb, and Nancy Stephens, also flags leadership and management infrastructure and physician alignment as valuation drivers distinct from financial metrics, since centers dependent on one or two physicians or lacking a transferable management layer carry higher post-close execution risk that buyers price into their offers.

Why It Matters

Operators who treat RCM cleanup as a back-office cost center are leaving valuation on the table. Standardizing collections, payer mix discipline, and management depth well before a sale process starts is now a direct lever on exit multiple, not just an efficiency project.

ASC valuation EBITDA multiples RCM performance exit readiness ASC sale process physician alignment buyer diligence

While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.

Frequently asked questions

What EBITDA multiples are ASCs selling for in 2026?

VMG Health reports ASC sale multiples have historically run 7-8x EBITDA, with best-in-class centers commanding double-digit multiples. Buyers are increasingly scrutinizing revenue cycle performance, not just case volume, when underwriting those premiums.

Why does revenue cycle management affect an ASC’s sale valuation?

Buyers treat clean, well-documented RCM as a direct signal of EBITDA durability and reduce diligence risk discounts when collections, payer mix, and denial rates are tightly managed. Weak RCM performance raises buyer doubts about whether reported EBITDA will hold post-close, which can compress the multiple offered.

What else do buyers evaluate beyond financial performance when acquiring an ASC?

VMG Health notes buyers also weigh leadership and management infrastructure and physician alignment alongside financial and RCM metrics, since a center reliant on one or two physicians or lacking a transferable management layer carries more post-close execution risk.

Similar Posts

  • Optimizely Enters the AEO Race With Agent Visibility Analytics

    Bypaulgruensfelder

    Optimizely launched a full Answer Engine Optimization (AEO) platform on June 10, 2026, introducing Agent Visibility Analytics and a new data-sharing partnership with Conductor. Built inside Optimizely Analytics, the tool uses log-level data, not modeled estimates, to show which AI agents and crawlers are accessing a site’s content, classified by intent and broken out by funnel stage or topic area. The launch pairs that visibility layer with two autonomous agents: one that flags content gaps versus competitors in AI search results, and one that benchmarks AI-driven share of voice. The release follows similar AEO moves from Siteimprove, HubSpot, Webflow, and Sitecore, as Google’s AI Mode surpasses 1 billion monthly active users.

  • CMS Proposes 2027 Physician Payment Overhaul: MIPS Sunset and ACO Expansion

    Bypaulgruensfelder

    CMS’s proposed CY 2027 Physician Fee Schedule rule would sunset traditional MIPS reporting in 2029, replace it with specialty-focused MIPS Value Pathways covering roughly 98% of specialties, and make Medicare ACOs easier to join and more rewarding. The Medicare Shared Savings Program — which paid $4.1 billion in shared savings to 75% of its 476 ACOs for 2024 while generating about $2.5 billion in net Medicare savings — would gain new-entrant financial incentives, more predictable spending benchmarks, and the option to reduce beneficiary cost-sharing starting April 2027. CMS also proposes recalibrating physician payment rates, introducing MIPS Core Measures in 2027, and closing an APM incentive loophole worth an estimated $2.38 billion over a decade.

  • The Attribution Problem Your Board Doesn’t Understand

    Bypaulgruensfelder

    Healthcare marketing attribution is genuinely hard for multi-site groups because patient journeys are long, largely offline, and privacy-constrained—and a budget you can’t defend is a budget that gets cut. Strategy Collective’s Matt Lee argues perfect attribution doesn’t exist, but ‘good enough’ attribution is achievable through four moves: call tracking, redesigned patient intake questions, a blended market-level report, and separating brand demand from generated demand. The bigger fix is reframing the board conversation itself. Instead of asking ‘is marketing working?’, leaders should ask ‘how do we make Market B look like Market A?’—shifting from an unwinnable ROI-proof debate to a comparative, market-level view that drives real reallocation decisions.

  • Q3 2026 AI Trends: What Growth Leaders Need to Track

    Bypaulgruensfelder

    The most useful AI question for growth-stage leaders in Q3 2026 has shifted from what models can do to what results they actually deliver. Summit Partners’ AI and data science team flags five developments to track: the conversation has moved from capability to production results; the binding constraint is rarely the model itself but data, workflow, and integration; agents are evolving from assistants to actors, with trust as the real limiting factor; the underlying economics of AI are being rewritten; and leaders must separate genuine signal from noise while recognizing what work stays human. The throughline is disciplined execution—turning promising pilots into dependable, measurable production systems.

  • PE’s Quieter Playbook: Joint Ventures With Nonprofit Health Systems

    Bypaulgruensfelder

    Private equity firms are increasingly expanding in healthcare through joint ventures with nonprofit health systems rather than outright buyouts, according to a new report from the Private Equity Stakeholder Project. The report finds 21.4% of private equity-owned hospitals are held through joint venture arrangements with nonprofit systems, and the structure now spans hospitals, inpatient rehab, hospice, home health, behavioral health, ambulatory surgery centers and urgent care — likely an undercount, since the tally covers only publicly identifiable arrangements. Case studies include ventures involving Lifepoint Health, Compassus, Ardent Health Services and Ascension. PESP argues these JVs have drawn far less scrutiny than traditional PE buyouts even as they become more common, prompting calls for greater oversight.

  • Why Penn Medicine Is Deploying AI Agents for Patient Intake

    Bypaulgruensfelder

    Penn Medicine is integrating K Health’s AI-powered patient intake agents into its virtual primary care service, testing whether an AI ‘team member’ in the patient-provider relationship improves outcomes. The agents collect symptoms and medical history before a visit and convert them into structured summaries that feed directly into the clinician’s existing workflow — providers start appointments already informed, and patients get routed to the right level of care. The same K Health technology already runs inside virtual care programs at Cedars-Sinai, Mayo Clinic, Mass General Brigham and Hartford HealthCare, with use cases ranging from new-patient acquisition to expanding primary care access. If the pilot succeeds, Penn plans to extend the agents into in-person primary care offices and specialty clinics.